Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Mallucci G, Dickinson A, Linehan J, Klöhn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 2003 Oct 31;302(5646):871-4. PubMed Abstract

  
Comments on Paper and Primary News
  Primary News: A Potential Prion Therapy Focuses Attention on Protein Conversion

Comment by:  Einar Sigurdsson (Disclosure)
Submitted 4 November 2003  |  Permalink Posted 4 November 2003

This is an elegant study that shows the importance of studying further the biological role of PrPC, and the intermediates that are formed during the conversion of PrPC to PrPSc. It is interesting to compare these findings to the Alzheimer's field, where little neurotoxicity is associated with Aβ plaques in mouse models, and certain Aβ species may be responsible for Aβ-induced neurotoxicity.

View all comments by Einar Sigurdsson

  Primary News: A Potential Prion Therapy Focuses Attention on Protein Conversion

Comment by:  Charles Glabe, ARF Advisor
Submitted 10 November 2003  |  Permalink Posted 10 November 2003

A requirement for intraneuronal PrPsc conversion in prion pathogenesis: What questions does this raise about the mechanism of AD pathogenesis?

The recent report by John Collinge and colleagues provides important new insight into the mechanisms of pathogenesis of prion disease, and raises some interesting questions about the corresponding mechanism for Alzheimer’s disease (AD) pathogenesis. They report that specifically depleting PrPc in neurons at 10-12 weeks reversed the early spongiform degeneration and dramatically prevented neuronal death and clinical disease, even though PrPsc accumulated extracellularly to the same level observed in diseased control animals. These results indicate that prion pathogenesis is intimately associated with the conformational conversion of PrPc to PrPsc in neurons, and that the extracellular accumulation of PrPsc is not toxic per se.

Do these results have heuristic value as an analogy for AD pathogenesis? AD and prion pathogenesis share some interesting pathogenic...  Read more


  Primary News: A Potential Prion Therapy Focuses Attention on Protein Conversion

Comment by:  Mary Reid
Submitted 2 November 2003  |  Permalink Posted 19 November 2003

This study finding that depletion of normal prion protein prevents or reverses the clinical manifestations of Creutzfeldt-Jacob disease is interesting.

Is it overexpresed as is APP in Alzheimer's disease?

If the study by Kniazeva, Orman and Terranova finding that PDGF is an inhibitor of PrP is replicated in neuronal tissue, I wonder whether we could look at reasons why PDGF signaling may be inhibited as a cause of prion diseases.

I had been looking at the fact that chlostridium difficile toxin B inhibits CDC42, and wondered if that would be an alternative to Gleevec for the treatment of Alzheimer's disease. With that in mind, is it too far a stretch to question a C. difficile involvement in the development prion disease? Could inhibition of CDC42 result in reduced inhibition of PrP mRNA by PDGF? Garcia-Lechuz et al. find that extra-intestinal infections caused by C. difficile occurred without concomitant...  Read more

  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:

Sections were stained with haematoxylin and eosin (H&E) and immunostained for detection of astrocytosis (anti-GFAP polyclonal from DAKO, 1:500 dilution) and PrPSc deposition (monoclonal to PrP, ICSM 35). Beta galactosidase expression was detected by x-gal staining, with anti-GFAP, (as above) and NFH (200, Sigma, dilution 1:200). In immunoblot total PrP was detected with the use of ICSM35 antibody.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad